|
1
|
Wang DS, Pan CC, Lai HC and Huang JM:
Expression of HMGA1 and ezrin in laryngeal squamous cell carcinoma.
Acta Otolaryngol. 133:626–632. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Steuer CE, El-Deiry M, Parks JR, Higgins
KA and Saba NF: An update on larynx cancer. CA Cancer J Clin.
67:31–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Liu J, Hu W, Zhang Y, Sang J, Li H,
Ma T, Bo Y, Bai T, Guo H, et al: miR-424-5p promotes proliferation,
migration and invasion of laryngeal squamous cell carcinoma.
OncoTargets Ther. 12:10441–10453. 2019. View Article : Google Scholar
|
|
4
|
Yang Q, Sun J, Ma Y, Zhao C and Song J:
LncRNA DLX6-AS1 promotes laryngeal squamous cell carcinoma growth
and invasion through regulating miR-376c. Am J Transl Res.
11:7009–7017. 2019.PubMed/NCBI
|
|
5
|
Bonner J, Giralt J, Harari P, Spencer S,
Schulten J, Hossain A, Chang SC, Chin S and Baselga J: Cetuximab
and radiotherapy in laryngeal preservation for cancers of the
larynx and hypopharynx: A secondary analysis of a randomized
clinical trial. JAMA Otolaryngol Head Neck Surg. 142:842–849. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishimura G, Sano D, Arai Y, Hatano T,
Takahashi H, Tanabe T, Wada T, Morishita D and Oridate N: A
prospective clinical trial of the second-look procedure for
transoral surgery in patients with T1 and T2 laryngeal,
oropharyngeal, and hypopharyngeal cancer. Cancer Med. 8:7197–7206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishimura G, Sano D, Yabuki K, Arai Y,
Chiba Y, Tanabe T and Oridate N: The second-look procedure for
transoral videolaryngoscopic surgery for T1 and T2 laryngeal,
oropharyngeal, and hypopharyngeal cancer patients: Protocol for a
nonrandomized clinical trial. JMIR Res Protoc. 6:e2352017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strieth S, Ernst BP, Both I, Hirth D,
Pfisterer LN, Künzel J and Eder K: Randomized controlled
single-blinded clinical trial of functional voice outcome after
vascular targeting KTP laser microsurgery of early laryngeal
cancer. Head Neck. 41:899–907. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meek DW and Marcar L: MAGE-A antigens as
targets in tumour therapy. Cancer Lett. 324:126–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sang M, Lian Y, Zhou X and Shan B: MAGE-A
family: Attractive targets for cancer immunotherapy. Vaccine.
29:8496–8500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sang M, Wang L, Ding C, Zhou X, Wang B,
Wang L, Lian Y and Shan B: Melanoma-associated antigen genes - an
update. Cancer Lett. 302:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Plaen E, Arden K, Traversari C, Gaforio
JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B,
Lurquin C, et al: Structure, chromosomal localization, and
expression of 12 genes of the MAGE family. Immunogenetics.
40:360–369. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lian Y, Sang M, Ding C, Zhou X, Fan X, Xu
Y, Lü W and Shan B: Expressions of MAGE-A10 and MAGE-A11 in breast
cancers and their prognostic significance: A retrospective clinical
study. J Cancer Res Clin Oncol. 138:519–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lydiatt WM, Patel SG, O'Sullivan B,
Brandwein MS, Ridge JA, Migliacci JC, Loomis AM and Shah JP: Head
and neck cancers-major changes in the American Joint Committee on
Cancer eighth edition cancer staging manual. CA Cancer J Clin.
67:122–137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fidler IJ: The relationship of embolic
homogeneity, number, size and viability to the incidence of
experimental metastasis. Eur J Cancer. 9:223–227. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liotta LA, Saidel MG and Kleinerman J: The
significance of hematogenous tumor cell clumps in the metastatic
process. Cancer Res. 36:889–894. 1976.PubMed/NCBI
|
|
19
|
Batth IS, Mitra A, Rood S, Kopetz S,
Menter D and Li S: CTC analysis: An update on technological
progress. Transl Res. 212:14–25. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang L, Riethdorf S, Wu G, Wang T, Yang
K, Peng G, Liu J and Pantel K: Meta-analysis of the prognostic
value of circulating tumor cells in breast cancer. Clin Cancer Res.
18:5701–5710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bidard FC, Peeters DJ, Fehm T, Nolé F,
Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz
JA, Stebbing J, et al: Clinical validity of circulating tumour
cells in patients with metastatic breast cancer: A pooled analysis
of individual patient data. Lancet Oncol. 15:406–414. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Bono JS, Scher HI, Montgomery RB,
Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ
and Raghavan D: Circulating tumor cells predict survival benefit
from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar
|
|
23
|
Cohen SJ, Punt CJ, Iannotti N, Saidman BH,
Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et
al: Relationship of circulating tumor cells to tumor response,
progression-free survival, and overall survival in patients with
metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krebs MG, Sloane R, Priest L, Lancashire
L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G,
et al: Evaluation and prognostic significance of circulating tumor
cells in patients with non-small-cell lung cancer. J Clin Oncol.
29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hou JM, Krebs MG, Lancashire L, Sloane R,
Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et
al: Clinical significance and molecular characteristics of
circulating tumor cells and circulating tumor microemboli in
patients with small-cell lung cancer. J Clin Oncol. 30:525–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Balic M, Lin H, Williams A, Datar RH and
Cote RJ: Progress in circulating tumor cell capture and analysis:
Implications for cancer management. Expert Rev Mol Diagn.
12:303–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van de Stolpe A, Pantel K, Sleijfer S,
Terstappen LW and den Toonder JM: Circulating tumor cell isolation
and diagnostics: Toward routine clinical use. Cancer Res.
71:5955–5960. 2011. View Article : Google Scholar
|
|
28
|
Savino M, Garrubba M, Parrella P, Baorda
F, Copetti M, Murgo R, Zelante L, Carella M, Valori VM and Santini
SA: Development of real-time quantitative reverse transcription-PCR
for Her2 detection in peripheral blood from patients with breast
cancer. Clin Chim Acta. 384:52–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stutterheim J, Ichou FA, den Ouden E,
Versteeg R, Caron HN, Tytgat GA and van der Schoot CE: Methylated
RASSF1a is the first specific DNA marker for minimal residual
disease testing in neuroblastoma. Clin Cancer Res. 18:808–814.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Wang F, Ning N, Chen Q, Yang Z,
Guo Y, Xu D, Zhang D, Zhan T and Cui W: Patterns of circulating
tumor cells identified by CEP8, CK and CD45 in pancreatic cancer.
Int J Cancer. 136:1228–1233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH
and Kim CW: TTF-1 mRNA-positive circulating tumor cells in the
peripheral blood predict poor prognosis in surgically resected
non-small cell lung cancer patients. Lung Cancer. 71:209–216. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gervasoni A, Sandri MT, Nascimbeni R,
Zorzino L, Cassatella MC, Baglioni L, Panigara S, Gervasi M, Di
Lorenzo D and Parolini O: Comparison of three distinct methods for
the detection of circulating tumor cells in colorectal cancer
patients. Oncol Rep. 25:1669–1703. 2011.PubMed/NCBI
|
|
33
|
Kim DD, Yang CS, Chae HD, Kwak SG and Jeon
CH: Melanoma antigen-encoding gene family member A1-6 and hTERT in
the detection of circulating tumor cells following CD45- depletion
and RNA extraction. Oncol Lett. 14:837–843. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu S, Sang M, Xu Y, Gu L, Liu F and Shan
B: Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell
carcinoma and their prognostic significance: A retrospective
clinical study. Acta Otolaryngol. 136:506–513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Trippel A, Halling F, Heymann P, Ayna M,
Al-Nawas B and Ziebart T: The expression of melanoma-associated
antigen A (MAGE-A) in oral squamous cell carcinoma: An evaluation
of the significance for tumor prognosis. Oral Maxillofac Surg.
23:343–352. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Poojary M, Jishnu PV and Kabekkodu SP:
Prognostic value of melanoma-associated antigen-A (MAGE-A) gene
expression in various human cancers: A systematic review and
meta-analysis of 7428 patients and 44 studies. Mol Diagn Ther.
doi.org/10.1007/s40291-020-00476-5. PubMed/NCBI
|
|
37
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stemke-Hale K, Hennessy B, Mills GB and
Mitra R: Molecular screening for breast cancer prevention, early
detection, and treatment planning: Combining biomarkers from DNA,
RNA, and protein. Curr Oncol Rep. 8:484–491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sang M, Wu X, Fan X, Sang M, Zhou X and
Zhou N: Multiple MAGE-A genes as surveillance marker for the
detection of circulating tumor cells in patients with ovarian
cancer. Biomarkers. 19:34–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hart CD, Galardi F, Luca FD, Pestrin M and
Di Leo A: Circulating tumour cells as liquid biopsy in breast
cancer-advancing from prognostic to predictive potential. Curr
Breast Cancer Rep. 7:53–58. 2015. View Article : Google Scholar
|
|
41
|
Qiao YY, Lin KX, Zhang Z, Zhang DJ, Shi
CH, Xiong M, Qu XH and Zhao XH: Monitoring disease progression and
treatment efficacy with circulating tumor cells in esophageal
squamous cell carcinoma: A case report. World J Gastroenterol.
21:7921–7928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Marusyk A, Almendro V and Polyak K:
Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev
Cancer. 12:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Krawczyk N, Meier-Stiegen F, Banys M,
Neubauer H, Ruckhaeberle E and Fehm T: Expression of stem cell and
epithelial-mesenchymal transition markers in circulating tumor
cells of breast cancer patients. BioMed Res Int.
2014:415721–415731. 2014. View Article : Google Scholar : PubMed/NCBI
|
